A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-11

Study Completion Date

2031-08-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a national, multicenter, retrospective/prospective, observational study in Taiwan designed to assess effectiveness, safety, and usage of efanesoctocog alfa prophylaxis treatment in hemophilia A participants. The data related to efanesoctocog alfa effectiveness, safety and usage will be recorded prospectively during routine visits for up to 5 years following enrollment initiation and the retrospective data will be collected at least 12 months and up to 24 months prior to efanesoctocog alfa initiation. Joint imaging data will be collected in centers performing Joint U/S and/or MRI (≥6 years old). At least 12 months of retrospective data will also be collected from medical records, as available. Prospectively collected data will be recorded at routine clinical visits during a five-year follow-up period. The end of study is defined as the last participant's last visit. No intervention will be administered, and no study related visits are required.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830

Hemophilia A

RECRUITING PHASE4

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

NCT05911763

Hemophilia A

ACTIVE_NOT_RECRUITING

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

NCT05981274

Severe Hemophilia A Without Inhibitor

RECRUITING

Observational Study of Long-Term Joint Health Outcome in Hemophilia Patient

NCT04618237

Hemophilia Arthropathy

UNKNOWN

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

NCT06941870

Factor VIII Deficiency

RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Efanesoctocog alfa

Participants observed receiving treatment with efanesoctocog alfa for hemophilia A

Efanesoctocog alfa

Intervention Type DRUG

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Efanesoctocog alfa

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ALTUVIIIO BIVV001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants with all ages and diagnosis of moderate-severe hemophilia A without current and/or at least three years of un-detectable inhibitor (\<0.6 BU)
* Participants with moderate to severe hemophilia A as defined by FVIII level ≤ 5%
* Participants starting efanesoctocog alfa prophylaxis treatment as per standard of care no more than three months prior to the enrollment date
* Participants aged 6 years and older are able to undergo MRI examinations (sedation given, if necessary, and per investigator discretion)
* Participants are able to undergo joint examinations
* Physician's decision to treat the participant with efanesoctocog alfa is made prior to and independently of participation in the study
* Signed and dated informed consent provided by the participant, or by the participant's legally acceptable representative for participants under the legal age before any study-related activities are undertaken. Assent should be obtained for pediatric participants according to local regulations

Exclusion Criteria

* Participants with coagulation disorders other than hemophilia A
* Participants diagnosed with other known bleeding disorder
* Participants currently receive factor therapy and have signs of decreased response to FVIII therapy
* Participants with a baseline Radiological Pettersson score (PS) of greater than 6 for each individual ankle
* Enrollment in another concurrent clinical interventional study, or intake of an Investigational Medicinal Product within 3 months prior to inclusion in this study
* Pregnant female participants

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Eligible Sex

ALL

Accepts Healthy Volunteers

No